Iobenguane I-131 - Progenics Pharmaceuticals

Drug Profile

Iobenguane I-131 - Progenics Pharmaceuticals

Alternative Names: 131-I-metaiodobenzylguanidine; 131-I-MIGB; 131I-iobenguane - Progenics Pharmaceuticals; 131I-MIBG - Progenics Pharmaceuticals; 3-iodobenzylguanidine-I-123; Azedra; HSA I-131 MIBG; I-131 mIBG; I-131-iobenguane; Iobenguane-I123-injection; Iobenguane-I131; Iobenguane-sulfate; Iodine-123 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131 iobenguane - Progenics Pharmaceuticals; Iodine-131 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131-metaiodobenzylguanidine; Iodine-I-131-metaiodobenzylguanidine; m-Iodobenzylguanidine-sulfate; Meta-iodobenzylguanidine; Metaiodobenzylguanidine-I-123; Metaiodobenzylguanidine-I-131; Metaiodobenzylguanidine-sulfate; MIBG; MIP-120T; Ultratrace I-131-MIBG; Ultratrace iobenguane I 131; Ultratrace MIBG; Ultratrace-iobenguane-I-131

Latest Information Update: 07 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer Progenics Pharmaceuticals
  • Class Antineoplastics; Guanidines; Iodobenzenes; Radiopharmaceuticals; Small molecules; Sulfates
  • Mechanism of Action Cell death stimulants; Neuron inhibitors; Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neuroendocrine tumours
  • Phase II Neuroblastoma

Most Recent Events

  • 07 Aug 2018 Launched for Neuroendocrine tumours (In adolescents, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults) in USA (IV) (Progenics pipeline, August 2018)
  • 01 Aug 2018 Progenics Pharmaceuticals plans to launch Iobenguane I-131 for Neuroendocrine tumors
  • 30 Jul 2018 Registered for Neuroendocrine tumours (In adolescents, In adults, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top